JASN reports on possible role of gadodiamide and Nephrogenic Systemic Fibrosis
A study published by the Journal of the American Society of Nephrology written by researches at Copenhagen University Hospital in Denmark reports on its findings back in 2006. They found that Nephrogenic Systemic Fibrosis was a new, rare disease that affects patients with renal failure. Single cases led to the suspicion of the role of gadodiamide being used for magnetic resonance imaging. A study reviewed all of the confirmed cases of Nephrogenic Systemic Fibrosis with respect to clinical characteristics, gadodiamide exposure, and subsequent clinical course. It was found that all had been exposed to gadodiamide before the development of nephrogenic systemic fibrosis. The ratio for acquiring the disease when exposed to gadodiamide was seven (54%) patients became severely disabled, and one died 21 months after exposure. No other exposure or event related to gadodiamide was common in the patients that could be identified. These findings indicate that gadodiamide played a role in Nephrogenic Systemic Fibrosis.
